Clinical decision rules to improve the detection of adverse drug events in Emergency Department patients

Academic Emergency Medicine

Volumn 19, Issue 6, 2012, Pages 640-649

  Hohl, Corinne M ^a,b,c   Yu, Eugenia ^a,c   Hunte, Garth S ^a,d   Brubacher, Jeffrey R ^a,b,c   Hosseini, Faegheh ^e   Argent, Chelsea P ^a,f   Chan, Winnie W Y ^b   Wiens, Matthew O ^a   Sheps, Samuel B ^a   Singer, Joel ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^d ST PAUL S HOSPITAL   (Canada)

^e UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^f Vernon Jubilee Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORIDE; CODEINE; DIURETIC AGENT; GLIBENCLAMIDE; HYPERGLYCEMIC AGENT; HYPERTENSIVE AGENT; NARCOTIC ANALGESIC AGENT; OLANZAPINE; OPIATE; PARACETAMOL; PHENYTOIN; PREDNISONE; PSYCHOTROPIC AGENT; RAMIPRIL;

ADULT; ADVERSE DRUG REACTION; AMBULANCE; CLINICAL DECISION MAKING; COHORT ANALYSIS; COMORBIDITY; CONSULTATION; DIAGNOSTIC TEST; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NURSE; PHARMACIST; PHYSICIAN; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADULT; CANADA; DECISION SUPPORT TECHNIQUES; DRUG TOXICITY; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84862267691     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2012.01379.x     Document Type: Review

References (41)

1. Baker GR, Norton PG, Flintoft V, et al. The Canadian adverse events study: the incidence of adverse events among hospital patients in Canada. Can Med Assoc J. 2004; 170:1678-86. (Pubitemid 38758745)
2. Transport Canada. Road Safety in Canada. Fatalities - 1986-2005. Available at: http://www.tc.gc.ca/eng/roadsafety/tp-tp3322-2005-page4-652.htm. Accessed Feb 24, 2012.
3. World Health Organization. International drug monitoring: the role of the hospital. Report of a World Health Organization Meeting. World Health Organization Technical Report Series. 1966; 425:5-24.
4. Forster A, Asmis T, Clark H, et al. Ottawa hospital patient safety study: incidence and timing of adverse events in patients admitted to a Canadian teaching hospital. Can Med Assoc J. 2004; 170:1235-40. (Pubitemid 38553307)
5. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991; 324:377-84.
6. Nebeker J, Barach P, Samore M. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004; 140:795-801. (Pubitemid 38623529)
7. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001; 38:666-71. (Pubitemid 33131567)
8. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 365:2002-12.
9. Hohl CM, Robitaille C, Lord V, et al. Emergency physician recognition of adverse drug-related events in elder patients presenting to an emergency department. Acad Emerg Med. 2005; 12:197-205. (Pubitemid 40248878)
10. Zed PJ. Drug-related visits to the emergency department. J Pharm Pract. 2005; 18:329-35. (Pubitemid 43349737)
11. Zed PJ, Abu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. Can Med Assoc J. 2008; 178:1563-9. (Pubitemid 351860342)
12. Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279:1200-5. (Pubitemid 28193431)
13. Hohl CM, Nosyk B, Zed P, et al. Outcomes of emergency department patients presenting with adverse drug events. Ann Emerg Med. 2011; 58:270-9.
14. Hohl CM, Zed PJ, Brubacher JR, Abu-Laban RB, Loewen PS, Purssell R. Do emergency physicians attribute drug-related emergency department visits to medication-related problems? Ann Emerg Med. 2010; 55:493-502.
15. Classen D, Pestotnik S, Evans S, Lloyd J, Burke J. Adverse drug events in hospitalized patients. JAMA. 1997; 277:301-6.
16. Bates D, Spell N, Cullen D, et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997; 277:307-11. (Pubitemid 27045011)
17. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007; 27:481-93. (Pubitemid 46536228)
18. Bordet R, Gauthier S, Louet HL, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol. 2001; 56:935-41. (Pubitemid 33788573)
19. Classen D. Assessing the Effect of Adverse Hospital Events on the Cost of Hospitalization and Other Patient Outcomes. Salt Lake City, UT: University of Utah, 1993.
20. Hohl CM, Brubacher J, Singer J. Emergency physicians attitudes about routine screening for adverse drug events [abstract]. Can J Emerg Med. 2010; 12:260.
21. Hospital Pharmacy in Canada Editorial Board. 2007/08 Hospital Pharmacy in Canada Report. Available at: http://www.lillyhospitalsurvey.ca/hpc2/content/ 2008-report/2007-08-full.pdf. Accessed Feb 25, 2012.
22. Serour S, Zelovics M, Trudel N, Manoukian C. Pharmacist needed in the ER, Stat. Can J Hosp Pharm. 1999; 52:387-92.
23. Ackroyd-Stolarz S, Read Guernsey J, MacKinnon NJ, Kovacs G. The association between a prolonged stay in the emergency department and adverse events in older patients admitted to hospital: a retrospective cohort study. BMJ Qual Saf. 2011; 20:564-9.
24. Schull MJ, Vermeulen M, Slaughter G, Morrison L, Daly P. Emergency department crowding and thrombolysis delays in acute myocardial infarction. Ann Emerg Med. 2004; 44:577-85. (Pubitemid 39573174)
25. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45. (Pubitemid 12149145)
26. World Health Organization. Letter MIO/372/2(A). 1991. Available at: http://www.scribd.com/vinicius-barros/d/22293073-Adverse-Drug-Reactions- Definitions-Diagnosis-And-Management. Accessed Feb 24, 2012.
27. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000; 356:1255-9.
28. Hepler C, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990; 47:533-43. (Pubitemid 20138134)
29. Fleiss JL. Statistical Methods for Rates and Proportions, 3rd ed. Hoboken, NJ: John Wiley & Sons, Inc., 2003.
30. Stiell I, Wells G. Methodologic standards for the development of clinical decision rules in emergency medicine. Ann Emerg Med. 1999; 33:437-47. (Pubitemid 29157570)
31. The Joint Commission. National Patient Safety Standards. Available at: http://www.jointcommission.org/standards-information/npsgs.aspx. Accessed Feb 24, 2012.
32. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance-lack of vigilance, lack of trust. JAMA. 2004; 292:2647-50. (Pubitemid 39577521)
33. Wiktorowicz M, Lexchin J, Moscou K, Silversides A, Eggertson L. Keeping an eye on Prescription Drugs, Keeping Canadians Safe: Active Monitoring Systems for Drug Safety and Effectiveness in Canada and Internationally. Available at: http://publications.gc.ca/collections/collection-2011/ccs-hcc/H174-21-2010-eng. pdf. Accessed Feb 24, 2012.
34. Wiktorowicz M, Lexchin J, Paterson M, et al. Research networks involved in post-market pharmacosurveillance in the United States, United Kingdom, France, New Zealand, Australia, Norway and European Union: Lessons for Canada. In: Canadian Patient Safety Institute, Canadian Institutes of Health Research, 2008. Available at: http://www.patientsafetyinstitute.ca/English/research/ commissionedResearch/postMarketingSurveillance/Documents/Post- Marketing%20Pharmacosurveillance%20Final%20Report.pdf. Accessed Feb 24, 2012.
35. Health Canada. Adverse Drug Reactions. Available at: http://www.hc-sc.gc. ca/dhp-mps/homologationlicensing/system/map-carte/ar-ei-eng.php. Accessed Feb 24, 2012.
36. United States Department of Health & Human Services. MedWatch: The United States Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program. Available at: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/default.htm. Accessed Feb 24, 2012.
37. Piazza-Hepp T, Kennedy D. Reporting of adverse events to MEDWATCH. Am J Health Syst Pharm. 1995; 52:1436-9.
38. Budnitz DS, Pollock DA, Mendelsohn AB, Weidenbach KN, McDonald AK, Annest JL. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system. Ann Emerg Med. 2005; 45:197-206.
39. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006; 296:1858-66. (Pubitemid 44596195)
40. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006; 26:601-8. (Pubitemid 43673042)
41. Nelson T, Budnitz D, Weidenbach K, Kegler S, Pollock D, Mendelsohn A. Assessing the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project-Six Sites, United States, January 1-June 15, 2004. MMWR Morb Mortal Wkly Rep. 2005; 54:380-3.